These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 35237863)

  • 41. The Effect of Iron Supplementation on FGF23 in Chronic Kidney Disease Patients: a Systematic Review and Time-Response Meta-Analysis.
    Abu-Zaid A; Magzoub D; Aldehami MA; Behiry AA; Bhagavathula AS; Hajji R
    Biol Trace Elem Res; 2021 Dec; 199(12):4516-4524. PubMed ID: 33462793
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Induction of cardiac FGF23/FGFR4 expression is associated with left ventricular hypertrophy in patients with chronic kidney disease.
    Leifheit-Nestler M; Große Siemer R; Flasbart K; Richter B; Kirchhoff F; Ziegler WH; Klintschar M; Becker JU; Erbersdobler A; Aufricht C; Seeman T; Fischer DC; Faul C; Haffner D
    Nephrol Dial Transplant; 2016 Jul; 31(7):1088-99. PubMed ID: 26681731
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Oral Ferric Maltol for the Treatment of Iron-Deficiency Anemia in Patients With CKD: A Randomized Trial and Open-Label Extension.
    Pergola PE; Kopyt NP
    Am J Kidney Dis; 2021 Dec; 78(6):846-856.e1. PubMed ID: 34029682
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effects of lower versus higher phosphate diets on fibroblast growth factor-23 levels in patients with chronic kidney disease: a systematic review and meta-analysis.
    Tsai WC; Wu HY; Peng YS; Hsu SP; Chiu YL; Chen HY; Yang JY; Ko MJ; Pai MF; Tu YK; Hung KY; Chien KL
    Nephrol Dial Transplant; 2018 Nov; 33(11):1977-1983. PubMed ID: 29420827
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Phosphate Binder, Ferric Citrate, Attenuates Anemia, Renal Dysfunction, Oxidative Stress, Inflammation, and Fibrosis in 5/6 Nephrectomized CKD Rats.
    Jing W; Nunes ACF; Farzaneh T; Khazaeli M; Lau WL; Vaziri ND
    J Pharmacol Exp Ther; 2018 Oct; 367(1):129-137. PubMed ID: 30093458
    [TBL] [Abstract][Full Text] [Related]  

  • 46. FGF23: a mature renal and cardiovascular risk factor?
    Zoccali C; Yilmaz MI; Mallamaci F
    Blood Purif; 2013; 36(1):52-7. PubMed ID: 23735695
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Association of Fibroblast Growth Factor 23 With Atrial Fibrillation in Chronic Kidney Disease, From the Chronic Renal Insufficiency Cohort Study.
    Mehta R; Cai X; Lee J; Scialla JJ; Bansal N; Sondheimer JH; Chen J; Hamm LL; Ricardo AC; Navaneethan SD; Deo R; Rahman M; Feldman HI; Go AS; Isakova T; Wolf M;
    JAMA Cardiol; 2016 Aug; 1(5):548-56. PubMed ID: 27434583
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effects of Nicotinamide and Lanthanum Carbonate on Serum Phosphate and Fibroblast Growth Factor-23 in CKD: The COMBINE Trial.
    Ix JH; Isakova T; Larive B; Raphael KL; Raj DS; Cheung AK; Sprague SM; Fried LF; Gassman JJ; Middleton JP; Flessner MF; Block GA; Wolf M
    J Am Soc Nephrol; 2019 Jun; 30(6):1096-1108. PubMed ID: 31085679
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Inflammation regulates fibroblast growth factor 23 production.
    Francis C; David V
    Curr Opin Nephrol Hypertens; 2016 Jul; 25(4):325-32. PubMed ID: 27191351
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The role of bone in CKD-mediated mineral and vascular disease.
    Khouzam NM; Wesseling-Perry K; Salusky IB
    Pediatr Nephrol; 2015 Sep; 30(9):1379-88. PubMed ID: 25168424
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Endocrine fibroblast growth factors as potential biomarkers for chronic kidney disease.
    Kondo Y; Komaba H; Fukagawa M
    Expert Rev Mol Diagn; 2020 Jul; 20(7):715-724. PubMed ID: 32513031
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effect of ferric carboxymaltose on serum phosphate and C-terminal FGF23 levels in non-dialysis chronic kidney disease patients: post-hoc analysis of a prospective study.
    Prats M; Font R; García C; Cabré C; Jariod M; Vea AM
    BMC Nephrol; 2013 Jul; 14():167. PubMed ID: 23902731
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Lipocalin-2: a novel link between the injured kidney and the bone.
    Courbon G; David V
    Curr Opin Nephrol Hypertens; 2022 Jul; 31(4):312-319. PubMed ID: 35727169
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Ferric Citrate Dosing in Iron Deficiency Anemia in Nondialysis-Dependent Chronic Kidney Disease.
    Pergola PE; Belo D; Crawford P; Moustafa M; Luo W; Goldfarb-Rumyantzev A; Farag YMK
    Am J Nephrol; 2021; 52(7):572-581. PubMed ID: 34293738
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Conventional and novel impacts of ferric citrate on iron deficiency anemia and phosphorus metabolism in rats.
    Iida A; Matsushita M; Ohta T; Yamada T
    J Vet Med Sci; 2020 Mar; 82(3):379-386. PubMed ID: 31996496
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Longitudinal evaluation of FGF23 changes and mineral metabolism abnormalities in a mouse model of chronic kidney disease.
    Stubbs JR; He N; Idiculla A; Gillihan R; Liu S; David V; Hong Y; Quarles LD
    J Bone Miner Res; 2012 Jan; 27(1):38-46. PubMed ID: 22031097
    [TBL] [Abstract][Full Text] [Related]  

  • 57. New insights into the FGF23-Klotho axis.
    Olauson H; Vervloet MG; Cozzolino M; Massy ZA; Ureña Torres P; Larsson TE
    Semin Nephrol; 2014 Nov; 34(6):586-97. PubMed ID: 25498378
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effect of a Ferric Citrate Formulation, a Phosphate Binder, on Oxidative Stress in Chronic Kidney Diseases-Mineral and Bone Disorder Patients Receiving Hemodialysis: A Pilot Study.
    Tanaka M; Miyamura S; Imafuku T; Tominaga Y; Maeda H; Anraku M; Yamasaki K; Kadowaki D; Ishima Y; Watanabe H; Okuda T; Itoh K; Matsushita K; Fukagawa M; Otagiri M; Maruyama T
    Biol Pharm Bull; 2016; 39(6):1000-6. PubMed ID: 27251502
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Randomized trial of intravenous iron-induced hypophosphatemia.
    Wolf M; Chertow GM; Macdougall IC; Kaper R; Krop J; Strauss W
    JCI Insight; 2018 Dec; 3(23):. PubMed ID: 30518682
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Associations Between Intravenous Iron, Inflammation and FGF23 in Non-Dialysis Patients with Chronic Kidney Disease Stages 3-5.
    Muras-Szwedziak K; Nowicki M
    Kidney Blood Press Res; 2018; 43(1):143-151. PubMed ID: 29444509
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.